A 31-Year-Old Woman with a Transformed Low-Grade Glioma
JAMA 303:967-976, Warnke,P.C., 2010
Progress Toward Mitigating Disability Progression in Multiple Sclerosis
NEJM 392:1966-1968, Calabresi,P.A., 2025
Neurological Events Reported after COVID-19 Vaccines: An Analysis of Vaccine Adverse Event Reporting System
Ann Neurol 91:756-771, Frontera, J.A.,et al, 2022
US Case Reports of Cerebral Venous Sinus Thrombosis with Thrombocytopenia after Ad26.COV2.S Vaccination, March 2 to April 21, 2021
JAMA 325:2448-2456,2445, See, I.,et al, 2021
Vaccine-Induced Thrombocytopenia with Severe Headache
NEJM 385:doi:101056/NE0a2114255, Schonborn, L., et al, 2021
Vaccine-Induced Thrombocytopenia with Severe Headache
NEJM 385:doi:10.1056/NEJMc2112974, Salih, F.,et al, 2021
Acute Maternal Confusion and Neonatal Seizure Postpartum
BMJ 364:k5399, Jakes, A.D.,et al, 2019
A young woman with symmetric weakness and behavioral disturbance
Neurol 90:e1442-e1447, Rosenberg, J.,et al, 2018
A 56-year-old woman with acute vertigo and diplopia
Neurol 90:748-752, Sharma, R.,et al, 2018
Drug Reaction with Eosinophilia and Systemic Symptoms after Daclizamub Therapy
Neurol 91:e359-e363, Rauer,S.,et al, 2018
Clinicopathologic Conference, Copper Deficiency Myelopathy
NEJM 377:1977-1984, Case 35-2017, 2017
Restless Legs Syndrome Associated with Major Diseases
Neurol 86:1336-1343, Trenkwalder, C.,et al, 2016
Opioids for Low Back Pain
BMJ 350:g6380, Deyo, R.A.,et al, 2015
Ischemic Optic Neuropathies
NEJM 372:2428-2436, Biousse, V. & Newman, N.J., 2015
ICU-Acquired Weakness and Recovery from Critical Illness
NEJM 370:1626-1635, Kress, J.P. & Hall, J.B., 2014
Everolimus Long-Term Safety and Efficacy in Subependymal Giant Cell Astrocytoma
Neurol 80:574-580, Krueger, D.,et al, 2013
Acute Symptomatic Seizures
The Neurologist 18:109-119, Beleza,P., 2012
Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis
NEJM 367:1098-1106,1149, Gold, R.,et al, 2012
Tumefactive Multiple Sclerosis Lesions under Fingolimod Treatment
Neurol 79:2000-2002,1942, Visser, F.,et al, 2012
Alemtuzumab for Multiples Sclerosis: Who and When to treat?
Lancet 380:1795-1797, 1792, Springer, T. & Kappos, L., 2012
Spectrum of Neurologic Complications in Chronic Lymphocytic Leukemia
Clin Lymphoma Myeloma Leuk 12:164-179, Lopes da Silva, R., 2012
Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy
Neurol 76:1697-1704, Vermersch,P.,et al, 2011
Mechanisms of Fingolimods Efficacy and Adverse Effects in Multiple Sclerosis
Ann Neurol 69:759-777, Cohen, J.A. & Chun, J., 2011
Reversible Cerebral Vasoconstruction Syndromes
Arch Neurol 68:1005-1012,976, Singhal, A.B.,et al, 2011
Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis
NEJM 365:1293-1303, OConnor, P.,et al, 2011
A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis
NEJM 362:416-426, 456, Giovannoni,G.,et al, 2010
A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis
NEJM 362:387-401, 456, Kappos, L.,et al, 2010
Immunologic, Clinical, and Radiologic Status 14 Months After Cessation of Natalizumab Therapy
Neurol 72:396-401,392, Stuve,O.,et al, 2009
Memantine Induces Reversible Neurologic Impairment in Patients with MS
Neurol 72:1630-1633, Villoslada,P.,et al, 2009
Reversible Cerebral Vasoconstriction Syndrome
Pract Neurol 9:256-267, Ducros,A. &Bousser,M.-G., 2009
Alemtuzumab vs. Interferon Beta-1a in Early Multiple Sclerosis
NEJM 359:1786-1801,1838, The CAMMS223 Trial Investigators, 2008
Statin Induced Myopathy
BMJ 337:1159-1162, Sathasivam,S. &Lecky,B., 2008
Risk Factors of Cerebral Vein and Sinus Thrombosis
Front Neurol Neurosci 23:23-54, de Freitas, G.R. & Bogousslavsky, J., 2008
Natalizumab Plus Interferon Beta -1a for Relapsing Multiple Sclerosis
NEJM 354:911-923,965, Rudick,R.A.,et al, 2006
A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis
NEJM 354:899-910,965, Polman,C.H.,et al, 2006
Hyponatremia in Neurologic Patients: Consequences and Approaches to Treatment
The Neurologist 12:117-126, Diringer,M.N. &Zazulia,A., 2006
Spectrum and Prognosis of Neurologic Complications After Hematopoietic Transplantation
Neurol 67:1990-1997, Denier,C.,et al, 2006
Effects of Reviparin, a Low-Molecular-Weight Heparin, on Mortality, Reinfarction, and Strokes in Patients With Acute Myocardial Infarction Presenting With ST-Segment Elevation
JAMA 293:427-436, The CREATE Trial Group Investigators, 2005
Treatment of Early Onset Multiple Sclerosis With Subcutaneous Interferon Beta-1a
Neurol 64:888-890, 778, Pohl,D., et al, 2005
Heparin-Induced Thrombocytopenia in Neurologic Patients Treated with Low-Molecular-Weight Heparin
Neurol 64:1285-1287, Pohl,C.,et al, 2005
The Reproductive Effects of Beta Interferon Therapy in Pregnancy, A longitudinal Cohort
Neurol 65:807-811,788, Boskovic,R.,et al, 2005
Acute Disseminated Encephalomyelitis
Arch Neurol 62:1673-1680, Menge,T.,et al, 2005
Hyponatremia from Oxcarbazepine and Carbamazepine
Neurol 65:1976-1978, Dong,X.,et al, 2005
Clopidogrel-Associated TTP, An Update of Pharmacovigilance Efforts
Stroke 35:533-538, Zakarija,A.,et al, 2004
Mitoxantrone Treatment of Multiple Sclerosis
Neurol 63(Suppl 6):S28-S32, Cohen,B.A. &Mikol,D.D., 2004
Migraine--Current Understanding and Treatment
NEJM 346:257-270, Goadsby,P.J.,et al, 2002
Disease-Modifying Therapy in Multiple Sclerosis: Strategies for Optimizing Management
The Neurologist 8:227-236, Frohman,E.,et al, 2002
Intraspinal Steroids: History, Efficacy, Accidentality, and Controversy with Review of United States Food and Drug Administration Reports
JNNP 70:433-443, Nelson,D.A. & Landau,W.M., 2001
Tinzaparin in Acute Ischaemic Stroke (TAIST):A Randomised Aspirin-Controlled Trial
Lancet 358:702-710,683, Bath,P.M.W.,et al, 2001